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Abstract. Earlier studies have shown that modification of
the octapeptide octreotide in positions 3 and 8 may result
in compounds with increased somatostatin receptor affin-
ity that, if radiolabelled, display improved uptake in so-
matostatin receptor-positive tumours. The aim of a recent
research study in our laboratory was to employ the paral-
lel peptide synthesis approach by further exchanging the
amino acid in position 3 of octreotide and coupling the
macrocyclic chelator DOTA(1,4,7,10-tetraazacyclodode-
cane-1,4,7,10-tetraacetic acid) to these peptides for label-
ling with radiometals like gallium-67 or -68, indium-111,
yttrium-90 and lutetium-177. The purpose was to find ra-
diopeptides with an improved somatostatin receptor bind-
ing profile in order to extend the spectrum of targeted tu-
mours. A first peptide, [111In,90Y-DOTA]-1-Nal3-octreo-
tide (111In,90Y-DOTA-NOC), was isolated which showed
an improved profile. InIII-DOTA-NOC exhibited the fol-
lowing IC50 values (nM) when studied in competition
with [125I][Leu8, D-Trp22, Tyr25]somatostatin-28 (values
for YIII-DOTA-NOC are shown in parentheses): sstr2,
2.9±0.1 (3.3±0.2); sstr3, 8±2 (26±1.9); sstr5, 11.2±3.5
(10.4±1.6). Affinity towards sstr1 and 4 was very low or
absent. InIII-DOTA-NOC is superior to all somatostatin-
based radiopeptides having this particular type of binding
profile, including DOTA-lanreotide, and has three to four
times higher binding affinity to sstr2 than InIII,YIII-
DOTA-Tyr3-octreotide (InIII,YIII-DOTA-TOC). In addi-
tion, [111In]DOTA-NOC showed a specific and high rate
of internalization into AR4-2J rat pancreatic tumour cells
which, after 4 h, was about two times higher than that of
[111In]DOTA-TOC and three times higher than that of
[111In]DOTA-octreotide ([111In]DOTA-OC). The internal-
ized radiopeptides were externalized intact upon 2 h of
internalization followed by an acid wash. After 2–3 h of
externalization a plateau is reached, indicating a steady-
state situation explained by reactivation of the receptors
followed by re-endocytosis. Biodistribution studies in CA
20948 tumour-bearing rats showed rapid clearance from
all sstr-negative tissues except the kidneys. At 4 h the up-
take of [111In]DOTA-NOC in the tumour and sstr-positive
tissues, such as adrenals, stomach and pancreas, was
three to four times higher than that of [111In]DOTA-TOC.
Differential blocking studies indicate that this is at least
partially due to the uptake mediated by sstr3 and sstr5.
These very promising preclinical data justify the use of
this new radiopeptide for imaging and potentially internal
radiotherapy studies in patients.
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Introduction
Radiopeptides are becoming of increasing interest in tu-
mour targeting for either the localization or the internal
radiotherapy of neoplasms [1, 2, 3, 4, 5, 6, 7, 8, 9]. Ana-
logues of the somatotropin release inhibiting factor
Abbreviations of the common amino acids are in accordance with
the recommendations of IUPAC-IUB [IUPAC-IUB Commission
of Biochemical Nomenclature (CBN), Symbols for amino-acid de-
rivatives and peptides, recommendations 1971. Eur J Biochem
1972; 27:201–207].
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(SRIF), somatostatin, radiolabelled with a variety of gam-
ma-, positron- and beta-emitters, are the prototypes of
such peptides. Somatostatin is a cyclic peptide hormone
that occurs naturally in two bioactive molecular forms:
somatostatin-14 and its N-terminally extended form, so-
matostatin-28. It exerts different biological effects in dif-
ferent parts of the body such as the brain, the pituitary,
the pancreas, the gut and some components of the im-
mune system. The effects include inhibition of hormone
secretion and modulation of neurotransmission and cell
proliferation. These actions are mediated by specific, G-
protein-coupled receptors. Today five different somato-
statin receptor subtypes have been characterized and
cloned (sstr1–5). They are responsible for different bio-
logical responses. As some of these receptors are over-
expressed in several human tumours, especially neuroen-
docrine tumours and their metastases, these tumours can
be visualized in vivo by radiometal chelator conjugated
somatostatin analogues like [111In-DTPA-D-Phe1]-octreo-
tide (OctreoScan) [10]. It has also been shown that so-
matostatin receptor scintigraphy using this agent is the
most sensitive method for localization of primary and
metastatic disease in endocrine pancreatic tumours and
carcinoids except insulinomas [11]. New conjugates may
show higher sensitivity with regard to the localization of
tumours and metastases, e.g. 99mTc-depreotide is regis-
tered in many countries and appears to show good perfor-
mance in the evaluation of solitary pulmonary nodules
[12], in breast tumours and even in melanoma [13]. On
the other hand, a recent study comparing OctreoScan
with 99mTc-depreotide in 44 patients with neuroendocrine
tumours showed that the 111In-labelled peptide yielded a
far higher detection rate for neuroendocrine tumours, es-
pecially for liver metastases [14]. 111In]DOTA-TOC and
[90Y]DOTA-TOC (DOTA = 1,4,7,10-tetraazacyclodode-
cane-1,4,7,10-tetraacetic acid) have been shown to be ef-
fective targeting and therapeutic agents in animal models
and patients [15, 16, 17, 18, 19, 20, 21, 22, 23]. In addi-
tion, replacement of the alcohol group at the C-terminus
of the octapeptide by a carboxylic acid group led to in-
creased sstr2 affinity [24], and [177Lu-DOTA]-D-Phe1-
Tyr3-Thr8-octreotide ([177Lu]DOTA-TATE) showed high-
er tumour uptake than [111In-DTPA]-octreotide in six pa-
tients with somatostatin receptor-positive tumours [25].
These new radiopeptides show distinctly higher sstr2 af-
finity compared with OctreoScan. Nevertheless, they bind
with high affinity only to sstr2: their affinity to sstr5 is
low, and that to sstr3 almost negligible; no affinity of
these new compounds was found to sstr1 and sstr4. Al-
though the majority of tumours studied with radiolabelled
somatostatin analogues express mainly sstr2 [26], recent
literature data indicate that also sstr1 and sstr3–5 may be
present in some human tumours. For example, in binding
studies using [125I]-RC-160 (D-Phe-Cys-Tyr-D-Trp-Lys-
Val-Cys-Trp-NH2; KD=6.55 nM) as the radioligand, 
Halmos et al. [27] found somatostatin receptors to be
present on 76% of human epithelial ovarian cancers. By
use of in situ hybridization, Reubi et al. found m-RNAs
of sstr1, 2 and 3 in a variety of human tumours, including
GH-adenoma [28]. Forssell-Aronsson et al. reported the
lack of sstr2 (except for medullary thyroid carcinoma)
with Northern blot in most of the thyroid tumours studied
in 68 patients. Nevertheless, all tumour types regularly
expressed sstr1, sstr3, sstr4 and sstr5 [29]. Raderer et al.
could visualize primary pancreatic adenocarcinoma in vi-
vo with [111In]DOTA-lanreotide (LAN; D-2-Nal-Cys-Tyr-
D-Trp-Lys-Val-Cys-Thr-NH2) but not with [111In]DTPA-
octreotide [30]. Traub et al. reported [111In]DOTA-LAN
to have a high sensitivity for detection of lung cancer
[31]. However, their claim that this peptide targets
sstr2–5 with high affinity and sstr1 with lower affinity
could not be confirmed by Reubi et al. [24]. To extend
the biological activity profile of radiolabelled somatosta-
tin analogues, we started a programme to synthesize ra-
diopeptides with affinity to all somatostatin receptor sub-
types in order to potentially extend the spectrum of acces-
sible tumours in diagnosis and internal radiotherapy. A
first compound resulted from a parallel synthesis ap-
proach exchanging the amino acid in position 3 of octreo-
tide; this led to a radiopeptide, [111In/90Y-DOTA]-1-Nal3-
octreotide ([111In/90Y]DOTA-NOC), which had improved
affinity to sstr2 and high affinity to sstr3 and sstr5 when
compared with our lead compound [111In/90Y]DOTA-
TOC.
Here we present the preclinical evaluation of this pep-
tide with regard to binding affinity, rate of internalization
and biodistribution in a tumour-bearing rat model and
compare its properties with those of [111In/90Y-DOTA0-
Tyr3]-octreotide and [111In/90Y-DOTA0]-octreotide.
Materials and methods
All chemicals were obtained from commercial sources and used
without further purification. H-Thr(tBu)-ol-(2-chloro-trityl)-resin
was obtained from Advanced ChemTech (Giessen, Germany) and
Fmoc (9-fluorenylmethoxycarbonyl) amino acids were purchased
from NovaBiochem AG (Läufelfingen, Switzerland), Bachem
(Bubendorf, Switzerland) and Neosystems (France). 111InCl3 was
obtained from Mallinckrodt Medical (Petten, The Netherlands).
The prochelator DOTA(tBu)3 (4,7,10-tricarboxymethyl-tert-butyl
ester 1,4,7,10-tetraazacyclododecane-1-acetate) was synthesized
according to Heppeler et al. [32] or purchased from Macrocyclics
(Richardson, Tex., USA). The reactive side chains of the amino
acids were masked with one of the following groups: Cys, acet-
amidomethyl; Lys, t-butoxycarbonyl; Thr, t-butyl; Trp, t-butoxy-
carbonyl. Analytical reversed-phase high-performance liquid chro-
matography (RP-HPLC) was carried out on a Hewlett Packard
1050 HPLC system (Waldbronn, Germany) equipped with a multi-
wavelength detector and a flow-through Berthold LB506C1 gam-
ma-detector. Preparative HPLC was done on a Bischof HPLC
system (Metrohm AG, Switzerland) with HPLC-pumps 2250 and
a Lambda 1010 UV detector (Metrohm AG, Switzerland).
CC250/4 Nucleosil 120-3C18 columns from Macherey-Nagel
were used for analytical HPLC, and a VP250/21 Nucleosil 200-
5C15 column for preparative HPLC. The gradient systems consist-
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ed of mixtures of water with 0.1% trifluoroacetic acid (TFA) (sol-
vent A) and acetonitrile (solvent B). Quantitative gamma-counting
was performed on a COBRA 5003 gamma-system well counter
from Packard Instrument Company (Switzerland). Electrospray
ionization mass spectrometry (ESI-MS) was carried out with a
Finnigan SSQ 7000 spectrometer (Bremen, Germany).
Synthesis. The peptide-chelator conjugates were synthesized by
standard Fmoc solid phase synthesis [33] on 2-chlorotritylchloride
resin (substitution 0.8 mmol/g) on a Rink peptide-synthesizer
Switch 24 (RinkCombichem Technologies, Bubendorf, Switzer-
land), according to the general procedure described previously
[32]. The last step was the coupling of the prochelator DOTA(tBu)3
to the N-terminus of the peptide. Cleavage of the fully protected
conjugates from the resin, oxidative cyclization using iodine, de-
protection and HPLC purification led to compounds 1–3 (Table 1,
Fig. 1), which could be labelled with “cold” or radioactive In3+ or
Y3+ (InIII, YIII). All compounds were lyophilized after purification
and characterized by ESI-MS and RP-HPLC. In each case the MS
spectra consisted of a major [M+2Na]2+ ion peak and some other
smaller peaks corresponding to [M+Na]+ and [M+3Na]3+ ions. All
peptide-chelator conjugates had a purity >95% confirmed by RP-
HPLC. The results are given in Table 1. The peptide-DOTA conju-
gates obtained were designated DOTA-NOC [DOTA0-D-Phe1-1-
Nal3]-octreotide), DOTA-OC [DOTA0-octreotide]) and DOTA-
TOC [DOTA0-Tyr3]-octreotide).
The DOTA-SRIF analogues were complexed with InCl3 (an-
hyd.) and Y(NO3)3·5 H2O, using the following procedure: ca.
20 µg of the respective DOTA-peptide was heated along with
1.5 eq. of the corresponding metal salt in 150 µl 0.2 M sodium ac-
etate buffer (pH 5) for 25 min. After cooling, 20 µl 0.1 M DTPA
(pH 5) was added to complex free metal ions. This mixture was
loaded onto a SepPak C18 cartridge (Millipore, Switzerland), acti-
vated using 5 ml MeOH followed by 10 ml H2O. [MIII(DTPA)]2−
was washed from the cartridge using water. The MIII-DOTA-pep-
tide was eluted with methanol and obtained in >97% purity after
evaporation of methanol. The radiopeptides were synthesized ac-
cording to Heppeler et al. [32] and obtained in >99% radiochemi-
cal purity at specific activities of >37 GBq/µmol peptide.
For internalization experiments, the DOTA-peptides were la-
belled to a specific activity of about 37 GBq/µmol peptide; excess
InCl3 was then added and the mixture was purified on a SepPak C18
cartridge as described above to afford [111In/InIII]DOTA-peptides.
Determination of the somatostatin receptor affinity profiles. Cells
stably expressing human sstr1–5 were grown as described previ-
ously [24]. All culture reagents were supplied by GIBCO/BRL and
Life Technologies (Grand Island, N.Y.). Cell membrane pellets
were prepared and receptor autoradiography was performed on pel-
let sections (mounted on microscope slides) as described in detail
previously [24]. For each of the tested compounds, complete dis-
placement experiments were performed with the universal somato-
statin radioligand [125I][Leu8,D-Trp22,Tyr25]somatostatin-28 using
increasing concentrations of the unlabelled peptide ranging from
0.1 to 1,000 nM. Somatostatin-28 was run in parallel as control us-
ing the same increasing concentrations. IC50 values were calculated
after quantification of the data using a computer-assisted image
processing system. Tissue standards (autoradiographic [125I]micro-
scales Amersham, UK) containing known amounts of isotopes,
cross-calibrated to tissue-equivalent ligand concentrations, were
used for quantification [24]. The concentrations of the peptide so-
lutions were measured by UV-spectroscopy (εNOC,280 mm=9,855).
Cell culture and radioligand internalization studies. Sst2 receptor
expressing AR4-2J cells were obtained from Novartis Pharma
(Basel, Switzerland). The AR4-2J cell line was maintained by se-
rial passage in mono-layers in Dulbecco’s Modified Eagle’s Medi-
um (DMEM), supplemented with 10% fetal bovine serum, amino
acids, vitamins and penicillin-streptomycin, in a humidified 5%
CO2/air atmosphere at 37°C. Viability of the cells and cell num-
bers were counted under a microscope with a “Neubauer’s count-
ing chamber”. For all cell experiments, the cells were seeded at a
density of 0.8–1.1 million cells/well in six-well plates and incubat-
ed overnight with internalization buffer to obtain a good cell ad-
herence. The loss of cells during the internalization experiments
was below 10%. When different radiolabelled peptides were com-
pared in cell experiments, the same cell suspension-containing
plates were used. Furthermore, the internalization rate was linearly
corrected to 1 million cells/well in all cell experiments.
Medium was removed from the six-well plates and cells were
washed once with 2 ml of internalization buffer (DMEM, 1% fetal
bovine serum, amino acids and vitamins, pH 7.4). Furthermore,
1.5 ml internalization buffer was added to each well and the plates
were incubated at 37°C for about 1 h. Thereafter approximately
500,000 cpm or 0.02 MBq/well 111In/115In-labelled peptides
(2.5 pmol/well) to a final concentration of 1.67 nM were added to the
medium and the cells were incubated at 37°C for the indicated time
periods in triplicate. Internalization was also studied using three dif-
ferent concentrations of [111In/115In]DOTA-NOC (0.15 pmol/well or
0.1 nM, 2.5 pmol/well or 1.67 nM, and 10 pmol/well or 6.67 nM). To
determine non-specific membrane binding and internalization, cells
were incubated with radioligand in the presence of 1 µM octreotide.
Cellular uptake was stopped by removing medium from the cells and
by washing twice with 1 ml of ice-cold phosphate-buffered saline
(PBS). Acid wash for 10 min with a 0.1 M glycine buffer pH 2.8 on
ice was also performed twice. This was shown previously to be suffi-
Fig. 1. Structural formulae of
the DOTA-conjugated peptides.
1, DOTA-1-Nal3-octreotide
(DOTA-NOC); 2, DOTA-oct-
reotide (DOTA-OC); 3, DOTA-
Tyr3-octreotide (DOTA-TOC)
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cient to remove >90% of receptor-bound radioligand. This procedure
was performed to distinguish between membrane-bound (acid-re-
leasable) and internalized (acid-resistant) radioligand. Finally, the
cells were treated with 1 N NaOH. The culture medium, the receptor-
bound and the internalized fraction were measured radiometrically in
a gamma-counter (Packard, Cobra II).
Radioligand externalization studies. AR4-2J cells (1 million) were
incubated with 2.5 pmol/well or 1.67 nM [111In/115In]-labelled
DOTA-NOC, DOTA-TOC or DOTA-OC for 120 min, then the
medium was removed and the wells were washed twice with 1 ml
ice-cold PBS. In each experiment an acid wash for 10 min on ice
with a glycine buffer of pH 2.8 was performed to remove the re-
ceptor-bound ligand. Cells were then incubated again at 37°C with
fresh externalization buffer (DMEM containing 1% fetal bovine
serum pH 7.4). After different time points the external medium
was removed for quantification of radioactivity in a gamma-coun-
ter and replaced with fresh 37°C externalization medium. Internal-
ized ligand was extracted in 1 N NaOH, removed and quantified in
a gamma-counter. The recycled fraction was expressed as a per-
centage of the total internalized amount per 1 million cells, and
the stability of the externalized peptides was determined using
HPLC after removal of the solvent by a centrifugal evaporator.
Biodistribution. Animal experiments were performed in compli-
ance with the regulations of our institutions and with generally ac-
cepted guidelines governing such work. Male Lewis rats
(200–250 g) bearing the CA20948 pancreatic tumour (0.4–3.5 g)
were used in the experiments. Rats were injected under ether ana-
esthesia with 2–3 MBq of 0.34 nmol (0.5 µg total peptide mass)
[111In]DOTA-NOC in 0.5 ml saline into the dorsal vein of the pe-
nis. At several time points, rats were sacrificed under ether anaes-
thesia. Organs and blood were collected and the radioactivity in
these samples was determined using a gamma-counter.
In order to determine the non-specific uptake of the radiopep-
tides, rats were injected with 0.5 mg octreotide in 0.5 ml saline as
a co-injection with the radioligand.
To study the sstr2-, 3- and 5-related specific uptake of
[111In]DOTA-NOC in the SRIF receptor-positive tissues, blocking
studies were designed with two different somatostatin analogues:
DTPA-TATE (sstr2-selective ligand) and InIII-DOTA-NOC (sstr2,
3, and 5 affinity). Twenty-five micrograms of these peptides was
co-injected with 2–3 MBq [111In]DOTA-NOC (0.34 nmol in
0.5 ml saline) into the dorsal vein of the penis of non-tumour-bear-
ing male Lewis rats. Rats were sacrificed at 24 h and the organs of
interest collected and counted for radioactivity.
Statistical methods. Student’s t test was used to determine statisti-
cal significance. Differences at the 95% confidence level (P<0.05)
were considered significant.
Results
Synthesis and radiolabelling
The three DOTA-coupled octapeptides (Fig. 1) were ob-
tained by parallel synthesis on a trityl chloride resin and
are part of a small library. The peptides not reported here
will be discussed in a more comprehensive chemistry
publication. The overall yield of the DOTA peptides was
about 30% based on the first Fmoc cleavage. The pep-
tides were prepared and purified to >95% purity by
HPLC analysis.
Uncomplexed and metal ion-complexed DOTA pep-
tides were characterized by HPLC, by ESI-MS and by
the retained affinity to the somatostatin receptors. Some
selected analytical data are given in Table 1. Labelling
Table 1. Analytical data for each of the compounds
Compound number Compound name Mass spectrum HPLCa
Calculated M (Da) Observed M+Na+ (Da) TR (min) Purity (%)
1 DOTA-NOC 1,454.6 1,477.7 20.77 98.5
2 DOTA-OC 1,404.6 1,428.3 18.27 99.2
3 DOTA-TOC 1,420.6 1,444.3 16.1 99.0
a Elution system: flow 0.75 ml/min; A, 0.1% TFA in H2O; B, MeCN; linear gradient: 0–30 min, 10% B to 60% B. TR, elution time
Fig. 2. Elution profile of [111In]DOTA-TOC, [111In]DOTA-OC and
[111In]DOTA-NOC on the HPLC system described in Materials and
methods. The gradient applied was 0–30 min, 15% B to 40% B
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Fig. 3. Comparison of the internalization rate of [111In]DOTA-
NOC (■), [111In]DOTA-TOC (●) and [111In]DOTA-OC (▲) into
AR4-2J cells. Values and standard deviations are the result of
three independent experiments with triplicates in each experiment
and are expressed as specific internalization (percentage of dose
added to 1 million cells at 1.67 nM concentration, 37°C)
was performed in acetate buffer (pH 5, 0.4 M) by heating
at 95°C for 25 min, affording labelling yields with 111In
and 90Y of >99% at a specific activity of >37 GBq/µmol
peptide. The HPLC elution profile of the three 111In-la-
belled peptides is shown in Fig. 2. The respective RF
values are 17.03 min for [111In]DOTA-TOC, 18.83 min
for [111In]DOTA-OC and 20.88 min for [111In]DOTA-
NOC (for a gradient see the footnote to Table 1), indicat-
ing that this is the order of increasing lipophilicity.
Receptor binding and affinity profiles
Table 2 shows the IC50 values of the three radiopeptides
studied in this work as their YIII (InIII) complexed ver-
sions and of YIII-DOTA-LAN for the five somatostatin
receptor subtypes. The values were obtained by perform-
ing complete displacement experiments with the univer-
sal somatostatin radioligand [125I][Leu8, D-Trp22, Tyr25]-
somatostatin-28 on membranes from cells expressing the
receptor subtypes and were compared with the data for
somatostatin-28.
All compounds bound specifically to sstr2 with IC50
values between 3 and 23 nM. High specific binding af-
finities to sstr3 were also found for InIII-DOTA-NOC
(IC50=8±2 nM), YIII-DOTA-NOC (IC50=26±1.9 nM) and
YIII-DOTA-OC (IC50=27±8 nM). YIII-DOTA-TOC and
YIII-DOTA-LAN showed only very low affinities to sstr3
(IC50 ≥300 nM).
All metallopeptides also showed specific binding to
sstr5; YIII-DOTA-TOC bound with IC50=204±92 nM and
YIII-DOTA-OC with IC50=58±22 nM whereas YIII-
DOTA-LAN (IC50=16.3±3.4 nM) and YIII-DOTA-NOC
(IC50=10.4±1.6 nM) showed rather high affinities to sstr5.
In vitro internalization studies in AR4-2J cells
Figure 3 shows the results in respect of the time-
dependent internalization of [111In/115In]DOTA-NOC,
[111In/115In]DOTA-TOC and [111In/115In]DOTA-OC into
AR4-2J rat pancreatic tumour cells during a 240-min in-
Table 2. Affinity profiles (IC50) for human sst 1–5 receptors
Compound hsst1 hsst2 hsst3 hsst4 hsst5
SS-28 3.8±0.3 (10) 2.5±0.3 (11) 5.7±0.6 (10) 4.2±0.3 (11) 3.7±0.4 (11)
InIII-DOTA-NOC >10,000 (3) 2.9±0.1 (3) 8±2 (3) 227±18 (3) 11.2±3.5 (3)
YIII-DOTA-NOC >1,000 (3) 3.3±0.2 (3) 26±1.9 (3) >1,000 (3) 10.4±1.6 (3)
YIII-DOTA-TOC >10,000 (6) 11.4±1.7 (6) 389±136 (5) >10,000 (6) 204±92 (6)
YIII-DOTA-OC >10,000 (5) 20±2.2 (5) 27±8 (5) >1000 (5) 58±22 (4)
YIII-DOTA-LAN >10,000 (4) 22.8±4.9 (4) 290±105 (4) >1000 (4) 16.3±3.4 (4)
IC50 values are in nM (mean±SEM). Number of independent stud-
ies is given in parentheses. SS-28 was used as control
Using an assay based on rat brain cortex membranes and [125I]-
Tyr3-octreotide as radioligand, InIII-DOTA-D-Phe1-octreotide and
InIII-DOTA-Tyr3-octreotide were shown to be equipotent to the
corresponding YIII-DOTA-peptides (data not shown or Heppeler et
al. [32])
Fig. 4. Comparison of the percentage (± standard deviation) of ra-
diopeptide internalized into AR4-2J cells (1 million cells, 37°C)
after 30 min with different radiopeptide concentrations. Symbols
are as in Fig. 3
cubation period at 37°C. About 85%–95% of totally in-
ternalized ligand was specifically internalized. At
30 min and 1.67 nM concentration, [111In]DOTA-NOC
showed 7.2%±1.0% specific cell uptake of the total ac-
tivity administered which increased to 24.8%±1.6% up-
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take at 4 h. A tendency to reach a plateau was found at
24 h for all three peptides (data not shown). The uptake
of [111In]DOTA-OC at 30 min was only 1.0%±0.2% and
increased to 7.5%±0.3% at 4 h, whereas [111In]DOTA-
TOC showed 2.0%±0.7% internalization at 30 min, ris-
ing to 11.6%±0.8% at 4 h. The percentage of internal-
ized peptide measured at 30 min as a function of con-
centration is shown in Fig. 4.
The rate of externalization is shown in Fig. 5. In these
experiments, 111In labelled peptides were allowed to in-
ternalize for 120 min; cells were then washed twice with
PBS before removing the receptor-bound ligand with the
glycine buffer. Medium was then added and removed af-
ter 10 min, 30 min, 60 min, 120 min and 240 min and
measured for radioactivity. Up to 60 min, the three pep-
tides showed insignificant differences in the externaliza-
tion rate. Thereafter the extent of externalized ligand was
highest for [111In]DOTA-OC, with about 60% at 4 h
compared with 47%±4% for [111In]DOTA-NOC and
Fig. 5. Comparison of the externalization rate (± standard devia-
tion) after 120-min internalization of the three radiopeptides. Sym-
bols are as in Fig. 3
Table 3. Biodistribution and tissue radioactivity ratios in organs, blood and CA 20948 tumour of rats 4 h, 24 h and 48 h after injection of
[111In]DOTA-NOC and [111In]DOTA-TOC
Time Organ [111In]DOTA-TOC P [111In]DOTA-NOC [111In]-DOTA-NOC 
unblocked, n=3 rats unblocked, n=5 rats blockedc, n=3 rats
4 h Blooda 0.014±0.001
24 h Blooda 0.002±0.000 0.009 0.003±0.0005 0.003±0.0001
4 h Kidneysa 1.91±0.07
24 h Kidneysa 2.32±0.13 <0.0001 1.73±0.14 1.88±0.02
48 h Kidneysa 1.81±0.14
4 h Livera 0.18±0.018
24 h Livera 0.05±0.000 0.0004 0.11±0.020 0.10±0.008
24 h Spleena 0.04±0.000 0.0001 0.05±0.009 0.05±0.007
4 h Femurb 0.127±0.010
24 h Femurb 0.05±0.010 0.0004 0.098±0.016 0.022±0.005
48 h Femurb 0.084±0.014
4 h Pancreasb 2.57±0.08 <0.0001 7.75±1.39
24 h Pancreasb 1.70±0.13 0.01 2.93±0.69 0.33±0.05
4 h Adrenalsb 3.62±0.14 <0.0001 7.43±0.42
24 h Adrenalsb 3.19±0.27 <0.0001 7.21±1.02 1.32±0.28
48 h Adrenalsb 1.80±0.13 <0.0001 5.85±0.60
4 h Stomachb 0.91±0.12
24 h Stomachb 0.25±0.04 0.0014 0.56±0.13 0.08±0.01
4 h Pituitaryb 1.48±0.07 019 ns 1.66±0.20
24 h Pituitaryb 1.22±0.03 0.064 ns 1.89±0.55 0.21±0.06
4 h Tumourb 1.15±0.16 0.0004 3.86±0.63
24 h Tumourb 1.12±0.11 0.021 2.08±0.62 0.36±0.10
48 h Tumourb 0.51±0.04 <0.0001 2.04±0.29
Tumour to tissue ratios
24 h Tumour/blood 520 693
24 h Tumour/liver 22.4 18.9
4 h Tumour/kidneys 2.02
24 h Tumour/kidneys 0.48 1.20
48 h Tumour/kidneys 1.12
Values are the mean of % ID/g±SE
a Somatostatin receptor-negative organs
b Somatostatin receptor-positive organs
c Blocked with 0.5 mg octreotide as a co-injection with the radio-
peptide
43%±2% for [111In]DOTA-TOC. At 4 h the externaliza-
tion curve of all peptides showed a plateau. Study of the
chemical structure of the externalized [111In]DOTA-NOC
and [111In]DOTA-TOC by HPLC gave no indication of
metabolites. The peptides externalized were intact.
Biodistribution studies in rats
The 4-h, 24-h and 48-h uptake values of [111In]DOTA-
NOC and [111In]DOTA-TOC in sst receptor-positive or-
gans, including pancreas, adrenals, pituitary, stomach
and CA 20948 rat pancreatic tumour, as well as the kid-
neys, liver, spleen, femur and blood are shown in Ta-
ble 3. Both radiopeptides displayed rapid blood clear-
ance with less than 0.02% ID/g remaining in the blood at
4 h. There was also fast clearance from all sstr-negative
tissues except the kidneys. The excretion of both pep-
tides was mainly by the kidneys. [111In]DOTA-NOC had
a significantly higher uptake than [111In]DOTA-TOC in
all sstr-positive tissues at all time points, e.g. at 4 h (tu-
mour, 3.9%±0.6% ID/g vs 1.15%±0.16% ID/g; pancreas,
7.75%±1.4% ID/g vs 2.57%±0.08% ID/g; adrenals,
7.43%±0.42% ID/g vs 3.62%±0.14% ID/g; pituitary,
1.66%±0.20% ID/g vs 1.48%±0.07% ID/g).
To estimate the uptake in sstr-positive organs which may
be due to receptor subtype expression other than sstr2, in vi-
vo blocking studies were performed in normal rats using
different blocking agents like [DTPA0-Tyr3-Thr8]-octreotide
(DTPA-TATE), an sstr2-specific ligand (IC50=3.9±1 nM),
and InIII-DOTA-NOC (IC50: sstr2=2.9±0.1 nM, sstr3=
8±2 nM, sstr5=11.2±3.5 nM). In the adrenals, blocking with
only 25 µg of InIII-DOTA-NOC showed a very efficient re-
duction of about 95% whereas 25 µg of the sstr2-selective
ligand DTPA-TATE resulted in only about 75% blocking.
A significantly higher blocking effect was also found
with InIII-DOTA-NOC in the pancreas, pituitary and
stomach (data not shown).
Discussion
Receptor scintigraphy with 111In-DTPA-octreotide has
become the “gold standard” for the localization, staging
and management of neuroendocrine tumours [34]. The
high sensitivity of somatostatin receptor scintigraphy
and its ability to change the management of patients with
neuroendocrine tumours has been demonstrated in sever-
al studies [35, 36, 37, 38, 39]. The same agent has been
used for receptor-mediated radionuclide therapy with
some success if injected in high doses (6 GBq every 4
weeks) for total doses of up to about 100 GBq [40, 41,
42]. This agent only binds with reasonably high affinity
to sstr2 and with low affinity to sstr5 [24]; in addition,
111In is not an ideal therapeutic radionuclide. Therefore
several groups have developed agents based on somato-
statin for improved targeting with positron emitters like
68Ga, 64Cu and the gamma emitter 111In, and most impor-
tantly for labelling with therapeutic radionuclides like
90Y and 177Lu. The most successful peptides have been
[Tyr3]-octreotide (TOC) and [Tyr3, Thr8]-octreotide (oct-
reotate = TATE) coupled to the macrocyclic chelator
DOTA (DOTA-TOC, DOTA-TATE) [32, 43, 44, 45].
These agents bind with high affinity only to sstr2. Al-
though sstr2 is probably the most abundantly expressed
SRIF receptor in human cancer [26], subtypes sstr1,
sstr3, sstr4 and sstr5 may also be of interest. So, our ap-
proach is focussed on the identification of analogues
with a pan-somatostatin binding profile carrying func-
tional groups for radiolabelling [46] and we have started
a programme to use parallel synthesis methods to pro-
duce DOTA-coupled octapeptides with the aim of im-
proving the affinity to subtypes other than 2 while main-
taining the sstr2 affinity. In a series of compounds we
found that [DOTA0-1-naphthyl3]-octreotide shows prom-
ising properties owing to its high affinity to sstr2, with
an IC50 value of 3.3±0.2 nM if complexed to YIII and
2.9±0.1 nM if complexed to InIII, which is three- to four-
fold higher than the corresponding value for YIII-DOTA-
TOC (IC50=11.4±1.7 nM). The new metallopeptides are
equipotent to somatostatin-28 on sstr2 and a factor of 7
more potent than YIII-DOTA-LAN. Moreover, they show
good affinity to sstr3 and are significantly more potent at
sstr5 than YIII-DOTA-LAN. These data do not confirm
the pan-somatostatin-like binding affinities of DOTA-
LAN published earlier by Smith-Jones et al. [47]. In ad-
dition, InIII- and YIII-DOTA-NOC show the highest af-
finities on sstr3. A metal ion dependence is found at
sstr3 and sstr4, InIII-DOTA-NOC being about three to
four times more potent than YIII-DOTA-NOC. A poten-
tial explanation for this phenomenon is the difference in
the coordination geometry of the two DOTA-metalIII
complexes, which was documented using 1H-NMR spec-
troscopy and X-ray crystallography [48]. YIII-DOTA-OC
and YIII-DOTA-NOC are equipotent on sstr3 and about a
factor of 6 less potent than the endogenous ligand. There
is no metal ion dependence in affinity to sstr5.
Cell uptake and release
In order to obtain a defined and homogeneous metallopep-
tide, [111In]DOTA-NOC was complexed with “cold” InIII
to yield [111In, 115In]DOTA-NOC. At 4 h of internaliza-
tion, [111In/115In]DOTA-NOC showed a factor of 2 higher
specific cell uptake than [111In/115In]DOTA-TOC and a
factor of about 3 higher than [111In/115In]DOTA-OC at
1.67 nM peptide concentration per 1 million cells. The dif-
ference was even more pronounced at 0.1 nM concentra-
tion (Fig. 4). This order follows the receptor affinity of the
three radiopeptides, indicating that receptor affinity is the
major factor determining the rate of internalization.
As the addition of excess cold octreotide inhibits 90%
of the uptake, it can be considered as specific and recep-
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affinity to sstr2, sstr3 and sstr5. The higher blocking effi-
ciency of InIII-DOTA-NOC in the adrenals, pancreas,
stomach and pituitary may indicate that part of the radio-
ligand uptake is due to the improved receptor subtype
profile. These organs have previously been shown to ex-
press different receptor subtypes, at least at the mRNA
level: sstr2: adrenals, pituitary and pancreas; sstr3: pitui-
tary, pancreas and stomach; sstr5: adrenals, pituitary,
pancreas and stomach [51].
In conclusion, we have developed a new radiopeptide
based on somatostatin which promises to target a broader
range of somatostatin receptors and concomitantly a
larger spectrum of tumours. These preclinical data indi-
cate that [111In]DOTA-NOC is superior to existing and
well-studied radiolabelled somatostatin analogues. In-
deed, the predictions from these preclinical studies have
been confirmed in initial clinical studies in which excel-
lent images of thyroid cancer patients have been ob-
tained. We assume that [90Y]/[177Lu]DOTA-NOC will
have similar favourable properties.
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